These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

613 related articles for article (PubMed ID: 36483551)

  • 1. Multiplexed engineering and precision gene editing in cellular immunotherapy.
    Biederstädt A; Manzar GS; Daher M
    Front Immunol; 2022; 13():1063303. PubMed ID: 36483551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genome Engineering for Next-Generation Cellular Immunotherapies.
    Park JJ; Lee KAV; Lam SZ; Tang K; Chen S
    Biochemistry; 2023 Dec; 62(24):3455-3464. PubMed ID: 35930700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing.
    Dimitri A; Herbst F; Fraietta JA
    Mol Cancer; 2022 Mar; 21(1):78. PubMed ID: 35303871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Explorations of CRISPR/Cas9 for improving the long-term efficacy of universal CAR-T cells in tumor immunotherapy.
    Naeem M; Hazafa A; Bano N; Ali R; Farooq M; Razak SIA; Lee TY; Devaraj S
    Life Sci; 2023 Mar; 316():121409. PubMed ID: 36681183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Engineering the next generation of CAR-NK immunotherapies.
    Biederstädt A; Rezvani K
    Int J Hematol; 2021 Nov; 114(5):554-571. PubMed ID: 34453686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining different CRISPR nucleases for simultaneous knock-in and base editing prevents translocations in multiplex-edited CAR T cells.
    Glaser V; Flugel C; Kath J; Du W; Drosdek V; Franke C; Stein M; Pruß A; Schmueck-Henneresse M; Volk HD; Reinke P; Wagner DL
    Genome Biol; 2023 Apr; 24(1):89. PubMed ID: 37095570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRISPR/Cas systems to overcome challenges in developing the next generation of T cells for cancer therapy.
    Huang D; Miller M; Ashok B; Jain S; Peppas NA
    Adv Drug Deliv Rev; 2020; 158():17-35. PubMed ID: 32707148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genome Editing for Engineering the Next Generation of Advanced Immune Cell Therapies.
    de Lima SCG; Fantacini DMC; Furtado IP; Rossetti R; Silveira RM; Covas DT; de Souza LEB
    Adv Exp Med Biol; 2023; 1429():85-110. PubMed ID: 37486518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Engineering chimeric antigen receptor-T cells for cancer treatment.
    Ye B; Stary CM; Li X; Gao Q; Kang C; Xiong X
    Mol Cancer; 2018 Feb; 17(1):32. PubMed ID: 29448937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy to get on point with base editing.
    Harbottle JA
    Drug Discov Today; 2021 Oct; 26(10):2350-2357. PubMed ID: 33857616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetical engineering for NK and T cell immunotherapy with CRISPR/Cas9 technology: Implications and challenges.
    Zhi L; Su X; Yin M; Zhang Z; Lu H; Niu Z; Guo C; Zhu W; Zhang X
    Cell Immunol; 2021 Nov; 369():104436. PubMed ID: 34500148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unlocking the potential of iPSC-derived immune cells: engineering iNK and iT cells for cutting-edge immunotherapy.
    Fang M; Allen A; Luo C; Finn JD
    Front Immunol; 2024; 15():1457629. PubMed ID: 39281684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Building Potent Chimeric Antigen Receptor T Cells With CRISPR Genome Editing.
    Liu J; Zhou G; Zhang L; Zhao Q
    Front Immunol; 2019; 10():456. PubMed ID: 30941126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
    Soriano V
    AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment.
    Mollanoori H; Shahraki H; Rahmati Y; Teimourian S
    Hum Immunol; 2018 Dec; 79(12):876-882. PubMed ID: 30261221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elucidation of CRISPR-Cas9 application in novel cellular immunotherapy.
    Quazi S
    Mol Biol Rep; 2022 Jul; 49(7):7069-7077. PubMed ID: 35122203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Next Generation Natural Killer Cells for Cancer Immunotherapy.
    Rossi F; Fredericks N; Snowden A; Allegrezza MJ; Moreno-Nieves UY
    Front Immunol; 2022; 13():886429. PubMed ID: 35720306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The application of CRISPR-Cas9 genome editing tool in cancer immunotherapy.
    Wu HY; Cao CY
    Brief Funct Genomics; 2019 Mar; 18(2):129-132. PubMed ID: 29579146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genome Editing in Engineered T Cells for Cancer Immunotherapy.
    Bonini C; Chapuis AG; Hudecek M; Guedan S; Magnani C; Qasim W
    Hum Gene Ther; 2023 Sep; 34(17-18):853-869. PubMed ID: 37694593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CRISPR/Cas9-based genome editing in the era of CAR T cell immunotherapy.
    Salas-Mckee J; Kong W; Gladney WL; Jadlowsky JK; Plesa G; Davis MM; Fraietta JA
    Hum Vaccin Immunother; 2019; 15(5):1126-1132. PubMed ID: 30735463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.